Industry Trends

Europe Gene Editing Market share was valued at USD 1 billion in 2019 and is expected to witness 14.9% CAGR from 2020 to 2026.

Get more details on this report - Request Free Sample PDF

Increasing R&D expenditures by pharmaceutical, research institutes, and biopharmaceutical companies will escalate the gene editing industry growth over the analysis period. Recent developments have added innovations in the gene editing techniques due to surging investments in R&D expenditures. As, gene editing has evolved rapidly from past few years that allows much precise and faster results than conventional techniques. Moreover, government and nongovernment organizations in Europe are actively funding start-ups and several established firms for developing innovative gene therapies, favouring the industry growth.

Europe Market, By Application

Based on application, the market is fragmented into cell line engineering, plant genetic engineering, animal genetic engineering and others. The cell line engineering segment will witness around 15% CAGR over the analysis period. Rising applications of cell-line engineering in stem cell research, particularly for induced pluripotent stem cells (iPSCs) will drive the segmental progression. T-cell editing is growing immensely in cell therapy applications. Several market participants such as Thermo Fisher are using its most recent CRISPR RNP reagents to knock out a T-cell receptor in patient-derived cells with around 95% efficiency in a single transfection. Hence, rising benefits of CRISPR technology in cell line engineering will provide lucrative growth opportunities.

Europe Market, By Technology

On the basis of technology, the gene editing market is segmented into Zinc Finger Nucleases (ZFNs), CRISPR/Cas9, TALENs and others. The CRISPR/Cas9 segment held more than 46.5% market share in 2019. CRISPR technology offers solutions for people living with the diseases that have limited treatment options. CRISPR edit the human genome and also personalize medicine that are used by individuals depending upon the needs, thus making it a preferable option among patients. Several industry players are aiming to develop innovations in the CRISPR/Cas9 that has increased its preference in research process, augmenting the segment growth.

Europe Market, By End-user

Get more details on this report - Request Free Sample PDF

Europe market, by end-user, includes research institutes, contract research organizations (CROs), and biotech & pharma companies. The contract research organizations (CROs) segment was valued more than USD 240 million in 2019 and is anticipated to show a lucrative growth over forthcoming years. Several CROs are developing advanced gene editing tools including CRISPR/Cas9 and TALENS technology. Med pace, PSI and ACF Bio services are major CROs that are working on developing advanced gene editing tools that secures the segmental growth. These CROs has specialized technical team working on advanced gene therapies and clinical operations with wide experience in innovative gene therapies for rare diseases. Thus, rising focus of CROs on developing innovative gene editing tools will propel industry growth.

Europe Market, By Country

Germany gene editing market accounted more than 18.5% market share in 2019 and is estimated to grow at a substantial rate over the forecast timeframe. The growth is attributable to the rising prevalence of chronic as well as genetic disorders including cancer that will positively impact the business growth. Rising number of people affected by chronic disorders such as congestive heart failure, diabetes in Germany will lead to surged demand for gene editing therapies. Increasing government initiatives for spreading awareness regarding advanced gene therapies for genetic disorders will further augment the industry growth. German Society for Gene Therapy is an association of scientists and doctors that focuses on discovering issues related to clinical and experimental gene therapy.

Competitive Market Share

Some of the leading corporate players operating in the industry are Thermo Fisher Scientific, Agilent Technologies, Integrated DNA Technologies, Agilent Technologies, Takara Bio, Origene Technologies, EMD Millipore (Merck KGAa), CRISPR Therapeutics, Horizon Discovery Ltd, Caribou Biosciences and others. The industry players are undertaking various business strategies such as collaborations, expansion and innovations to attract larger customer base. In June 2020, Intellia Therapeutics announced collaboration with Regeneron Pharmaceuticals to produce products for additional in vivo Cas9/CRISPR based therapies. This strategy will help the company in expanding its business.

 Industry Background

Gene editing technique is achieved using enzymes, majorly nucleases that were engineered to target a definite DNA sequence, where they make cuts into the DNA parts that allow the exclusion of existing DNA. The idea of using gene editing to alter traits or treat disease was intiated in the 1950s. In the mid-20^th century, researchers realized the sequence of bases in DNA is passed mostly from parent to offspring and a minor undesirable change in the sequence can trigger a disease later on. Till date, CRISPR has been used in wide area of disease diagnosis and therapies, and continues to amaze the research world with its high potential in several other applications.